Validation of the miniPIERS model and a prognostic model for perinatal death in hypertensive pregnancy: Insights from the PREECARDIA study in Guinea‐Bissau
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.70850 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Ruben Turé und 2 weiteren Autor:innen. Beteiligte Einrichtung: EPIUnit ITR, Institute of Public Health of the University Porto, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Pre-Eclampsia, Perinatal Death, Hypertension, Pregnancy-Induced. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Using data from the PREECARDIA study, we aimed to evaluate the performance of the miniPIERS model for adverse maternal outcomes and the prognostic model for perinatal death in Bissau.
Methods
We conducted an external validation of the two predictor models using prospectively collected data from women with preeclampsia recruited at Hospital Nacional Simão Mendes, in Guinea‐Bissau, between June 2023 and January 2025. Model performance was assessed by evaluating discrimination, calibration, and risk stratification across different probability thresholds.
Results
During this period, 140 preeclamptic women were recruited, of whom 50 were excluded from the analysis because they had incomplete predictor or outcome information. The miniPIERS model demonstrated poor discrimination (area under the receiver operating characteristic curve [AUROC]: 0.664, 95% confidence interval [CI]: 0.50–0.78) and suboptimal calibration, with Calibration‐in‐the large (CITL) = 0.27, slope: 0.53. The prognostic model for perinatal death showed good discrimination (AUROC: 0.854, 95% CI: 0.77–0.93) but marked miscalibration (CITL = 1.43, slope = 2.11). The risk stratification table indicated low sensitivity and positive predictive value across different probability thresholds for both models.
Conclusion
The miniPIERS model showed limited utility for risk prediction in this setting, where healthcare infrastructure and population characteristics differ from the model's development context. While the prognostic model for perinatal death showed better discrimination, its poor calibration and high baseline neonatal mortality in this setting suggest that the model's utility must be interpreted cautiously. Future research should focus on larger multicenter validation studies in similar low‐resource settings to optimize and adapt risk prediction tools for maternal conditions such as preeclampsia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EPIUnit ITR, Institute of Public Health of the University Porto, University of Porto, Porto, Portugal.
- Hospital Nacional Simão Mendes, Bissau, Guinea-Bissau.
- Department of Public Health Sciences, Forensic Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal.
- Faculty of Medicine, University Eduardo Mondlane, Maputo, Mozambique.
ORCID-Profile: Ruben Turé, Albertino Damasceno, Nuno Lunet
Zitieren
APA
Turé, R., Damasceno, A., & Lunet, N. (2026). Validation of the miniPIERS model and a prognostic model for perinatal death in hypertensive pregnancy: Insights from the PREECARDIA study in Guinea‐Bissau. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70850
Vancouver
Turé R, Damasceno A, Lunet N. Validation of the miniPIERS model and a prognostic model for perinatal death in hypertensive pregnancy: Insights from the PREECARDIA study in Guinea‐Bissau. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70850
BibTeX
@article{Tur2026,
author = {Turé, Ruben and Damasceno, Albertino and Lunet, Nuno},
title = {Validation of the miniPIERS model and a prognostic model for perinatal death in hypertensive pregnancy: Insights from the PREECARDIA study in Guinea‐Bissau},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.70850}
}
EUVIMED